Terms: = Ovarian cancer AND BRAF, MGC126806, 673, ENSG00000157764, MGC138284, RAFB1, P15056, B-raf 1, BRAF1, B-raf1 AND Treatment
110 results:
1. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
[TBL] [Abstract] [Full Text] [Related]
2. Evaluating the Prognostic Factors and Survival Rates of Endometrial cancer Patients in a Tertiary Referral Hospital in Northeast Thailand.
Wannasin R; Thinkhamrop K; Kelly M; Likitdee N
Asian Pac J Cancer Prev; 2024 Feb; 25(2):671-679. PubMed ID: 38415555
[TBL] [Abstract] [Full Text] [Related]
3. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
[TBL] [Abstract] [Full Text] [Related]
4. Overexpression of ABCC1 and ABCG2 confers resistance to talazoparib, a poly (ADP-Ribose) polymerase inhibitor.
Teng QX; Lei ZN; Wang JQ; Yang Y; Wu ZX; Acharekar ND; Zhang W; Yoganathan S; Pan Y; Wurpel J; Chen ZS; Fang S
Drug Resist Updat; 2024 Mar; 73():101028. PubMed ID: 38340425
[TBL] [Abstract] [Full Text] [Related]
5. Somatic Genomic and Transcriptomic Characterization of Primary ovarian Serous Borderline Tumors and Low-Grade Serous Carcinomas.
Stružinská I; Hájková N; Hojný J; Krkavcová E; Michálková R; Bui QH; Matěj R; Laco J; Drozenová J; Fabian P; Škapa P; Špůrková Z; Cibula D; Frühauf F; Jirásek T; Zima T; Méhes G; Kendall Bártů M; Němejcová K; Dundr P
J Mol Diagn; 2024 Apr; 26(4):257-266. PubMed ID: 38280423
[TBL] [Abstract] [Full Text] [Related]
6. Tumor-Specific Activity of Precision Medicines in the NCI-MATCH Trial.
Zhou I; Plana D; Palmer AC
Clin Cancer Res; 2024 Feb; 30(4):786-792. PubMed ID: 38109210
[TBL] [Abstract] [Full Text] [Related]
7. The use of fertility treatments among reproductive-aged women after cancer.
Kipling LM; Shandley LM; Mertens AC; Spencer JB; Howards PP
Fertil Steril; 2024 Apr; 121(4):578-588. PubMed ID: 38103881
[TBL] [Abstract] [Full Text] [Related]
8. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With
Meric-Bernstam F; Rothe M; Mangat PK; Garrett-Mayer E; Gutierrez R; Ahn ER; Cannon TL; Powell S; Krauss JC; Reynolds CM; von Mehren M; Behl D; Calfa CJ; Duvivier HL; Kaplan HG; Livingston MB; Sharma MR; Urba WJ; Grantham GN; Hinshaw DC; Gregory A; Halabi S; Schilsky RL
JCO Precis Oncol; 2023 Sep; 7():e2300385. PubMed ID: 38096472
[TBL] [Abstract] [Full Text] [Related]
9. Long term activity of vemurafenib in cancers with braf mutations: the ACSE basket study for advanced cancers other than braf
Blay JY; Cropet C; Mansard S; Loriot Y; De La Fouchardière C; Haroche J; Topart D; Tougeron D; You B; Italiano A; Le Brun-Ly V; Ferrero JM; Penel N; Fabbro M; Troussard X; Malka D; Ray-Coquard I; Leboulleux S; Fléchon A; Maubec E; Charles J; Dalle S; Taieb S; Garcia GCTE; Mandache AM; Colignon N; Gavrel M; Nowak F; Hoog Labouret N; Mahier Aït Oukhatar C; Gomez-Roca C
ESMO Open; 2023 Dec; 8(6):102038. PubMed ID: 37922690
[TBL] [Abstract] [Full Text] [Related]
10. treatment of Recurrent Low-grade Serous ovarian cancer With MEK Inhibitors: A Systematic Review.
Kulkarni A; Cooke C; Fazelzad R; Fung-Kee-Fung M; May T; Zigras T
Am J Clin Oncol; 2024 Jan; 47(1):11-16. PubMed ID: 37823720
[TBL] [Abstract] [Full Text] [Related]
11. Association of UBE2L6 and ABCB6 Expression With Platinum Resistance in Serous ovarian Carcinoma.
Shibahara M; Kurita T; Murakami M; Harada H; Koi C; Izumi H; Yoshino K
Anticancer Res; 2023 Aug; 43(8):3787-3792. PubMed ID: 37500176
[TBL] [Abstract] [Full Text] [Related]
12. The highs and lows of serous ovarian cancer.
Grisham RN; Manning-Geist BL; Chui MH
Cancer; 2023 Sep; 129(17):2613-2620. PubMed ID: 37366225
[TBL] [Abstract] [Full Text] [Related]
13. Histological and Genetic Diversity in ovarian Mucinous Carcinomas: A Pilot Study.
Razia S; Nakayama K; Yamashita H; Ishibashi T; Ishikawa M; Kanno K; Sato S; Kyo S
Curr Oncol; 2023 Apr; 30(4):4052-4059. PubMed ID: 37185420
[TBL] [Abstract] [Full Text] [Related]
14. Deep and lasting response and acquired resistance to brafV600E targeting in a low-grade ovarian cancer patient.
Anchisi S; Wolfer A; Bisig B; Missiglia E; Tiab A; Kamel EM; Michielin O; Coukos G; Homicsko K
Cancer Biol Ther; 2023 Dec; 24(1):2193116. PubMed ID: 36967525
[TBL] [Abstract] [Full Text] [Related]
15. A survey of open questions in adaptive therapy: Bridging mathematics and clinical translation.
West J; Adler F; Gallaher J; Strobl M; Brady-Nicholls R; Brown J; Roberson-Tessi M; Kim E; Noble R; Viossat Y; Basanta D; Anderson ARA
Elife; 2023 Mar; 12():. PubMed ID: 36952376
[TBL] [Abstract] [Full Text] [Related]
16. Erdheim-Chester Disease Involving the Left Uterine Adnexa: Mimicking an ovarian Carcinoma Clinically.
Zeng Y; Wang Q; Wang X; Jiang X; Yao H; Tang X
Int J Surg Pathol; 2023 Dec; 31(8):1532-1537. PubMed ID: 36855299
[TBL] [Abstract] [Full Text] [Related]
17. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis.
Hendrikse CSE; Theelen PMM; van der Ploeg P; Westgeest HM; Boere IA; Thijs AMJ; Ottevanger PB; van de Stolpe A; Lambrechts S; Bekkers RLM; Piek JMJ
Gynecol Oncol; 2023 Apr; 171():83-94. PubMed ID: 36841040
[TBL] [Abstract] [Full Text] [Related]
18. The adaptor protein VEPH1 interacts with the kinase domain of ERBB2 and impacts EGF signaling in ovarian cancer cells.
Kollara A; Burt BD; Ringuette MJ; Brown TJ
Cell Signal; 2023 Jun; 106():110634. PubMed ID: 36828346
[TBL] [Abstract] [Full Text] [Related]
19. Low grade serous ovarian cancer - A rare disease with increasing therapeutic options.
Zwimpfer TA; Tal O; Geissler F; Coelho R; Rimmer N; Jacob F; Heinzelmann-Schwarz V
Cancer Treat Rev; 2023 Jan; 112():102497. PubMed ID: 36525716
[TBL] [Abstract] [Full Text] [Related]
20. TCR CDR3-antigen chemical complementarity associated with poor ovarian cancer outcomes: A vestigial immune response to early cancer antigens?
Barker VR; Varkhedi M; Patel DN; Hsiang M; Chobrutskiy A; Chobrutskiy BI; Blanck G
Am J Reprod Immunol; 2023 Jan; 89(1):e13639. PubMed ID: 36317868
[TBL] [Abstract] [Full Text] [Related]
[Next]